

# Kristian Tonby

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6446277/publications.pdf>

Version: 2024-02-01

27  
papers

1,221  
citations

516710

16  
h-index

526287

27  
g-index

30  
all docs

30  
docs citations

30  
times ranked

2461  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial. <i>Journal of Internal Medicine</i> , 2022, 291, 241-243.	6.0	9
2	Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations. <i>Journal of Internal Medicine</i> , 2022, 291, 801-812.	6.0	38
3	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	2.9	46
4	Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors. <i>Journal of Leukocyte Biology</i> , 2021, 110, 177-186.	3.3	13
5	Elevated plasma sTIM-3 levels in patients with severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 92-98.	2.9	31
6	Serum ACE as a prognostic biomarker in COVID-19: a case series. <i>Apmis</i> , 2021, 129, 237-238.	2.0	6
7	A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries. <i>Frontiers in Immunology</i> , 2021, 12, 608846.	4.8	21
8	Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. <i>Journal of Neurology</i> , 2021, 268, 3574-3583.	3.6	56
9	Delirium is common in patients hospitalized with COVID-19. <i>Internal and Emergency Medicine</i> , 2021, 16, 1997-2000.	2.0	9
10	Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns. <i>Journal of Internal Medicine</i> , 2021, 290, 677-692.	6.0	20
11	Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 669623.	3.9	3
12	Regional performance variation in external validation of four prediction models for severity of COVID-19 at hospital admission: An observational multi-centre cohort study. <i>PLoS ONE</i> , 2021, 16, e0255748.	2.5	3
13	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1261-1269.	3.9	84
14	CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries. <i>Journal of Infection</i> , 2021, 83, 433-443.	3.3	4
15	Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. <i>European Respiratory Journal</i> , 2021, 57, 2003448.	6.7	243
16	A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. <i>Nature Communications</i> , 2021, 12, 6774.	12.8	34
17	Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease. <i>Frontiers in Immunology</i> , 2020, 11, 579849.	4.8	18
18	Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25018-25025.	7.1	279

#	ARTICLE	IF	CITATIONS
19	Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. <i>Scientific Reports</i> , 2020, 10, 21697.	3.3	65
20	Predicting severe COVID-19 in the Emergency Department. <i>Resuscitation Plus</i> , 2020, 4, 100042.	1.7	23
21	Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate <i>Mycobacterium tuberculosis</i> infection in aerosol-challenged mice. <i>Communications Biology</i> , 2019, 2, 288.	4.4	31
22	KLRG1-Expressing CD4 T Cells Are Reduced in Tuberculosis Patients Compared to Healthy <i>Mycobacterium tuberculosis</i> â€“Infected Subjects, but Increase With Treatment. <i>Journal of Infectious Diseases</i> , 2019, 220, 174-176.	4.0	2
23	The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in <i>Mycobacterium tuberculosis</i> infection. <i>BMC Infectious Diseases</i> , 2016, 16, 599.	2.9	29
24	IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. <i>Journal of Infection</i> , 2015, 70, 381-391.	3.3	76
25	IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in <i>Mycobacterium Tuberculosis</i> infection. <i>Scientific Reports</i> , 2015, 5, 9223.	3.3	45
26	Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors. <i>PLoS ONE</i> , 2015, 10, e0141903.	2.5	18
27	Low prevalence of positive interferon-gamma tests in HIV-positive long-term immigrants in Norway. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 180-187.	1.2	5